← Atlas Theme · spans 1 topics
Clearing a disease's signature biological biomarker does not guarantee functional clinical improvement.
Therapies that successfully neutralize underlying biological markers of damage or disease expression frequently fail to demonstrate real-world clinical or functional benefits in slowly progressing conditions.
1
Topics it spans
2
Findings citing it
—
Evidence window
The convergence
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Science & Health
Roche Discontinues Both Leading Huntington's Disease Programs in Major Gene-Silencing Setback The drug candidate successfully reduced the target biological biomarkers of disease, yet failed to show any functional or clinical benefit for patients.
Science & Health
AstraZeneca and Ionis' Wainua Fails Phase 3 CARDIO-TTRansform Trial in ATTR-CM Despite achieving large, sustained reductions in the disease's target serum TTR protein, the drug failed to show real-world clinical or survival benefit over the existing standard of care.